問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Kaohsiung Municipal Ta-Tung Hospital

Division of Infectious Disease

更新時間：2023-11-02

張維安Chang, Wei-An
  • Principal Investigator
  • Clinical Trial Experience (year)

  • weianchang@kmu.edu.tw

Recruiting Trial

44Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張維安

List

69Cases

2020-06-20 - 2027-12-31

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Not yet recruiting3Sites

Recruiting9Sites

Terminated1Sites

2026-06-01 - 2028-12-31

Phase II

Not yet recruiting
A phase IIb trial (ARGiNAUT) evaluating the efficacy, safety, and tolerability of AZD8965 in patients with idiopathic pulmonary fibrosis (IPF).

  • Condition/Disease

    Idiopathic pulmonary fibrosis

  • Test Drug

    AZD8965 Film-Coated Tablet

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting1Sites

2021-12-23 - 2024-12-31

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2022-01-01 - 2026-12-31

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2026-07-01 - 2029-12-31

Phase II

Not yet recruiting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

  • Condition/Disease

    Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  • Test Drug

    NS-863

Participate Sites
6Sites

Not yet recruiting1Sites

2022-09-30 - 2026-04-30

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2022-10-01 - 2028-06-22

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

2026-06-01 - 2028-12-31

Phase II

Not yet recruiting
A two-part Phase IIb randomized, multicenter, open-label comparative study to firstly evaluate the safety and efficacy trial of BV100 in combination with low dose polymyxin B plus ceftazidime/avibactam, or plus cefiderocol versus best available therapy in patients with hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia and bloodstream infection, suspected or confirmed to be due to carbapenem-resistant Acinetobacter baumannii calcoaceticus complex (CRABC), and secondly to evaluate the pharmacokinetics of BV100 in combination with low dose polymyxin B plus cefiderocol in patients with confirmed CRABC ventriculitis or meningitis.

  • Condition/Disease

    Ventilator Associated Bacterial Pneumonia (VABP) Hospital Acquired Bacterial Pneumonia (HABP) Blood Stream Infection Meningitis, Bacterial Ventriculitis, Infectious

  • Test Drug

    Aztreonam BV100 FETROJA Polymyxin B Zavicefta

Participate Sites
9Sites

Not yet recruiting1Sites

2023-03-10 - 2024-11-14

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting4Sites

2023-06-01 - 2025-12-31

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

1 2 3 4 5 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB